BioPharma Dive - Latest News

Lilly to buy pain drug developer SiteOne, challenging Vertex

The acquisition expands Lilly’s pain pipeline with a slate of drugs targeting ion channel proteins like NaV1.7 and NaV1.8.

May 27, 2025 - 18:50
 0
Lilly to buy pain drug developer SiteOne, challenging Vertex

The acquisition expands Lilly’s pain pipeline with a slate of drugs targeting ion channel proteins like NaV1.7 and NaV1.8.

Read More

Tags:

Previous Article

FDA sets COVID vaccine formula as RFK Jr. narrows guidance for shots

Next Article

ASCO: Alcohol-Associated Cancer Mortality Increased From 1990 to 2021

Related Posts

FDA leaders seek industry input on ‘listening tour’

FDA leaders seek industry input on ‘listening tour’

May 28, 2025  0

Regeneron defeats Amgen in PCSK9 case; 2 cell therapy biotechs cut staff

Regeneron defeats Amgen in PCSK9 case; 2 cell therapy b...

May 16, 2025  0

Novo pressures GLP-1 compounders as FDA ban takes hold

Novo pressures GLP-1 compounders as FDA ban takes hold

May 22, 2025  0